Young cancer patients who were unable to take a certain drug because of national supply shortages were more likely to relapse than those who received the preferred treatment, according to a report published in the New England Journal of Medicine. Researchers found that 75% of Hodgkin lymphoma patients who received a substitute medication, cyclophosphamide, stayed cancer-free for two years, compared with 88% who received the first-choice medication mechlorethamine.

Full Story:
ABC News

Related Summaries